請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73357
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 阮雪芬 | |
dc.contributor.author | Chen-Tsung Huang | en |
dc.contributor.author | 黃振綜 | zh_TW |
dc.date.accessioned | 2021-06-17T07:30:19Z | - |
dc.date.available | 2019-07-03 | |
dc.date.copyright | 2019-07-03 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-06-14 | |
dc.identifier.citation | Al-Lazikani, B., Banerji, U., and Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30, 679-692.
Alvarez, M.J., Subramaniam, P.S., Tang, L.H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E.V., Hagan, E.A., Bodei, L., Clemons, P.A., Dela Cruz, F.S., Dhall, D., Diolaiti, D., Fraker, D.A., Ghavami, A., Kaemmerer, D., Karan, C., Kidd, M., Kim, K.M., Kim, H.C., Kunju, L.P., Langel, U., Li, Z., Lee, J., Li, H., LiVolsi, V., Pfragner, R., Rainey, A.R., Realubit, R.B., Remotti, H., Regberg, J., Roses, R., Rustgi, A., Sepulveda, A.R., Serra, S., Shi, C., Yuan, X., Barberis, M., Bergamaschi, R., Chinnaiyan, A.M., Detre, T., Ezzat, S., Frilling, A., Hommann, M., Jaeger, D., Kim, M.K., Knudsen, B.S., Kung, A.L., Leahy, E., Metz, D.C., Milsom, J.W., Park, Y.S., Reidy-Lagunes, D., Schreiber, S., Washington, K., Wiedenmann, B., Modlin, I., and Califano, A. (2018). A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet 50, 979-989. Andrews, P., Thyssen, J., and Lorke, D. (1982). The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther 19, 245-295. Aran, D., Camarda, R., Odegaard, J., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., and Butte, A.J. (2017). Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun 8, 1077. Babichev, Y., Kabaroff, L., Datti, A., Uehling, D., Isaac, M., Al-Awar, R., Prakesch, M., Sun, R.X., Boutros, P.C., Venier, R., Dickson, B.C., and Gladdy, R.A. (2016). PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J Transl Med 14, 67. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M.F., Monahan, J.E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F.A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I.H., Cheng, J., Yu, G.K., Yu, J., Aspesi, P., Jr., de Silva, M., Jagtap, K., Jones, M.D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R.C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J.P., Gabriel, S.B., Getz, G., Ardlie, K., Chan, V., Myer, V.E., Weber, B.L., Porter, J., Warmuth, M., Finan, P., Harris, J.L., Meyerson, M., Golub, T.R., Morrissey, M.P., Sellers, W.R., Schlegel, R., and Garraway, L.A. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607. Basu, A., Bodycombe, N.E., Cheah, J.H., Price, E.V., Liu, K., Schaefer, G.I., Ebright, R.Y., Stewart, M.L., Ito, D., Wang, S., Bracha, A.L., Liefeld, T., Wawer, M., Gilbert, J.C., Wilson, A.J., Stransky, N., Kryukov, G.V., Dancik, V., Barretina, J., Garraway, L.A., Hon, C.S., Munoz, B., Bittker, J.A., Stockwell, B.R., Khabele, D., Stern, A.M., Clemons, P.A., Shamji, A.F., and Schreiber, S.L. (2013). An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161. Bertolini, F., Sukhatme, V.P., and Bouche, G. (2015). Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol 12, 732-742. Beyer, K., Goldstein, J., Ramakrishnan, R., and Shaft, U. (1999). When is 'nearest neighbor' meaningful? Proc 7th Int Conf Database Theory 1540, 217-235. Blei, D.M., Ng, A.Y., and Jordan, M.I. (2003). Latent Dirichlet allocation. J Mach Learn Res 3, 993-1022. Brignole, C., Marimpietri, D., Pastorino, F., Nico, B., Di Paolo, D., Cioni, M., Piccardi, F., Cilli, M., Pezzolo, A., Corrias, M.V., Pistoia, V., Ribatti, D., Pagnan, G., and Ponzoni, M. (2006). Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98, 1142-1157. Caldarelli, G., Pastor-Satorras, R., and Vespignani, A. (2004). Structure of cycles and local ordering in complex networks. Eur Phys J B 38, 183-186. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J., and Bork, P. (2008). Drug target identification using side-effect similarity. Science 321, 263-266. Carpenter, E.L., and Mosse, Y.P. (2012). Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nat Rev Clin Oncol 9, 391-399. Carter, D.R., Murray, J., Cheung, B.B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A.J., Issaeva, N., Biktasova, A., Atmadibrata, B., Sun, Y., Sokolowski, N., Ling, D., Kim, P.Y., Webber, H., Clark, A., Ruhle, M., Liu, B., Oberthuer, A., Fischer, M., Byrne, J., Saletta, F., Thwe le, M., Purmal, A., Haderski, G., Burkhart, C., Speleman, F., De Preter, K., Beckers, A., Ziegler, D.S., Liu, T., Gurova, K.V., Gudkov, A.V., Norris, M.D., Haber, M., and Marshall, G.M. (2015). Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7, 312ra176. Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.S., So, S., and Butte, A.J. (2017). Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat Commun 8, 16022. Chen, M., Wang, J., Lu, J., Bond, M.C., Ren, X.R., Lyerly, H.K., Barak, L.S., and Chen, W. (2009). The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48, 10267-10274. Cheung, N.K., and Dyer, M.A. (2013). Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13, 397-411. Cheung, N.K., Zhang, J., Lu, C., Parker, M., Bahrami, A., Tickoo, S.K., Heguy, A., Pappo, A.S., Federico, S., Dalton, J., Cheung, I.Y., Ding, L., Fulton, R., Wang, J., Chen, X., Becksfort, J., Wu, J., Billups, C.A., Ellison, D., Mardis, E.R., Wilson, R.K., Downing, J.R., Dyer, M.A., and St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome, P. (2012). Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062-1071. Chikamori, K., Grabowski, D.R., Kinter, M., Willard, B.B., Yadav, S., Aebersold, R.H., Bukowski, R.M., Hickson, I.D., Andersen, A.H., Ganapathi, R., and Ganapathi, M.K. (2003). Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 278, 12696-12702. Clarke, R., Ressom, H.W., Wang, A., Xuan, J., Liu, M.C., Gehan, E.A., and Wang, Y. (2008). The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 8, 37-49. Collins, I., and Workman, P. (2006). New approaches to molecular cancer therapeutics. Nat Chem Biol 2, 689-700. Corsello, S.M., Bittker, J.A., Liu, Z., Gould, J., McCarren, P., Hirschman, J.E., Johnston, S.E., Vrcic, A., Wong, B., Khan, M., Asiedu, J., Narayan, R., Mader, C.C., Subramanian, A., and Golub, T.R. (2017). The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med 23, 405-408. Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26, 1367-1372. D'Haeseleer, P. (2005). How does gene expression clustering work? Nat Biotechnol 23, 1499-1501. Dagogo-Jack, I., and Shaw, A.T. (2018). Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15, 81-94. Deroo, B.J., and Archer, T.K. (2001). Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell 12, 3365-3374. Deshwar, A.G., and Morris, Q. (2014). PLIDA: cross-platform gene expression normalization using perturbed topic models. Bioinformatics 30, 956-961. DuBois, S.G., Groshen, S., Park, J.R., Haas-Kogan, D.A., Yang, X., Geier, E., Chen, E., Giacomini, K., Weiss, B., Cohn, S.L., Granger, M.M., Yanik, G.A., Hawkins, R., Courtier, J., Jackson, H., Goodarzian, F., Shimada, H., Czarnecki, S., Tsao-Wei, D., Villablanca, J.G., Marachelian, A., and Matthay, K.K. (2015). Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 21, 2715-2721. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Colmet Daage, L., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Ne, P., Michon, J., Pugh, T.J., Hart, L.S., Rader, J., Attiyeh, E.F., Wei, J.S., Zhang, S., Naranjo, A., Gastier-Foster, J.M., Hogarty, M.D., Asgharzadeh, S., Smith, M.A., Guidry Auvil, J.M., Watkins, T.B., Zwijnenburg, D.A., Ebus, M.E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C.E., Westerhout, E.M., Schulte, J.H., Tytgat, G.A., Dolman, M.E., Janoueix-Lerosey, I., Gerhard, D.S., Caron, H.N., Delattre, O., Khan, J., Versteeg, R., Schleiermacher, G., Molenaar, J.J., and Maris, J.M. (2015). Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47, 864-871. Enright, A.J., Van Dongen, S., and Ouzounis, C.A. (2002). An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res 30, 1575-1584. Felix, M.A., and Barkoulas, M. (2015). Pervasive robustness in biological systems. Nat Rev Genet 16, 483-496. Feng, Y., Mitchison, T.J., Bender, A., Young, D.W., and Tallarico, J.A. (2009). Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 8, 567-578. Flemming, A. (2015). Anticancer drugs: Finding the perfect combination. Nat Rev Drug Discov 14, 13. Flentie, K., Gonzalez, C., Kocher, B., Wang, Y., Zhu, H., Marasa, J., and Piwnica-Worms, D. (2018). Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFkappaB Activation. Mol Cancer Res 16, 986-999. Fletcher, J.I., Haber, M., Henderson, M.J., and Norris, M.D. (2010). ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10, 147-156. Fletcher, J.I., Ziegler, D.S., Trahair, T.N., Marshall, G.M., Haber, M., and Norris, M.D. (2018). Too many targets, not enough patients: rethinking neuroblastoma clinical trials. Nat Rev Cancer 18, 389-400. Frayha, G.J., Smyth, J.D., Gobert, J.G., and Savel, J. (1997). The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 28, 273-299. Friedman, J., Hastie, T., and Tibshirani, R. (2008). Sparse inverse covariance estimation with the graphical lasso. Biostatistics 9, 432-441. Fu, J., Bian, M., Liu, J., Jiang, Q., and Zhang, C. (2009). A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc Natl Acad Sci U S A 106, 6939-6944. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R.J., Bignell, G.R., Tam, A.T., Davies, H., Stevenson, J.A., Barthorpe, S., Lutz, S.R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J.L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H.G., Chang, J.W., Baselga, J., Stamenkovic, I., Engelman, J.A., Sharma, S.V., Delattre, O., Saez-Rodriguez, J., Gray, N.S., Settleman, J., Futreal, P.A., Haber, D.A., Stratton, M.R., Ramaswamy, S., McDermott, U., and Benes, C.H. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575. Gewirtz, D.A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741. Goldenson, B., and Crispino, J.D. (2015). The aurora kinases in cell cycle and leukemia. Oncogene 34, 537-545. GTEx Consortium (2015). Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660. Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., Chen, J., Benes, C., Charron, E., Simonds, E.F., Seeger, R., Matthay, K.K., Hertz, N.T., Eilers, M., Shokat, K.M., and Weiss, W.A. (2014). Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26, 414-427. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. Hans, F., Skoufias, D.A., Dimitrov, S., and Margolis, R.L. (2009). Molecular Distinctions between Aurora A and B: A Single Residue Change Transforms Aurora A into Correctly Localized and Functional Aurora B. Mol Biol Cell 20, 3491-3502. Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.E., Krishnamurthy Radhakrishna, V., Siravegna, G., Hu, H., Raoof, S., Lockerman, E., Kalsy, A., Lee, D., Keating, C.L., Ruddy, D.A., Damon, L.J., Crystal, A.S., Costa, C., Piotrowska, Z., Bardelli, A., Iafrate, A.J., Sadreyev, R.I., Stegmeier, F., Getz, G., Sequist, L.V., Faber, A.C., and Engelman, J.A. (2016). Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22, 262-269. Hogarty, M.D., Norris, M.D., Davis, K., Liu, X., Evageliou, N.F., Hayes, C.S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., Keating, J., Thomas, W., Cheng, N.C., Murray, J., Smith, J., Sutton, R., Venn, N., London, W.B., Buxton, A., Gilmour, S.K., Marshall, G.M., and Haber, M. (2008). ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68, 9735-9745. Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013). Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726. Hopkins, A.L. (2007). Network pharmacology. Nat Biotechnol 25, 1110-1111. Hopkins, A.L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4, 682-690. Hsu, T.Y., Simon, L.M., Neill, N.J., Marcotte, R., Sayad, A., Bland, C.S., Echeverria, G.V., Sun, T., Kurley, S.J., Tyagi, S., Karlin, K.L., Dominguez-Vidana, R., Hartman, J.D., Renwick, A., Scorsone, K., Bernardi, R.J., Skinner, S.O., Jain, A., Orellana, M., Lagisetti, C., Golding, I., Jung, S.Y., Neilson, J.R., Zhang, X.H., Cooper, T.A., Webb, T.R., Neel, B.G., Shaw, C.A., and Westbrook, T.F. (2015). The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384-388. Huang, C.T., Hsieh, C.H., Chung, Y.H., Oyang, Y.J., Huang, H.C., and Juan, H.F. (2019a). Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery. iScience 15, 291-306. Huang, C.T., Hsieh, C.H., Lee, W.C., Liu, Y.L., Yang, T.S., Hsu, W.M., Oyang, Y.J., Huang, H.C., and Juan, H.F. (2019b). Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma. Clin Cancer Res DOI: 10.1158/1078-0432.CCR-18-4117 (in press). Huang, C.T., Hsieh, C.H., Oyang, Y.J., Huang, H.C., and Juan, H.F. (2018). A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning. iScience 7, 40-52. Hughes, T.R., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton, R., Armour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y.D., Kidd, M.J., King, A.M., Meyer, M.R., Slade, D., Lum, P.Y., Stepaniants, S.B., Shoemaker, D.D., Gachotte, D., Chakraburtty, K., Simon, J., Bard, M., and Friend, S.H. (2000). Functional discovery via a compendium of expression profiles. Cell 102, 109-126. Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., and di Bernardo, D. (2010). Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107, 14621-14626. Iorio, F., Knijnenburg, T.A., Vis, D.J., Bignell, G.R., Menden, M.P., Schubert, M., Aben, N., Goncalves, E., Barthorpe, S., Lightfoot, H., Cokelaer, T., Greninger, P., van Dyk, E., Chang, H., de Silva, H., Heyn, H., Deng, X., Egan, R.K., Liu, Q., Mironenko, T., Mitropoulos, X., Richardson, L., Wang, J., Zhang, T., Moran, S., Sayols, S., Soleimani, M., Tamborero, D., Lopez-Bigas, N., Ross-Macdonald, P., Esteller, M., Gray, N.S., Haber, D.A., Stratton, M.R., Benes, C.H., Wessels, L.F.A., Saez-Rodriguez, J., McDermott, U., and Garnett, M.J. (2016). A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740-754. Itamochi, H., Oishi, T., Shimada, M., Sato, S., Uegaki, K., Naniwa, J., Sato, S., Nonaka, M., Terakawa, N., Kigawa, J., and Harada, T. (2011). Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin Cancer Res 17, 4742-4750. Jackson, A.L., and Linsley, P.S. (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9, 57-67. Jacobsen, A., Silber, J., Harinath, G., Huse, J.T., Schultz, N., and Sander, C. (2013). Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol 20, 1325-1332. Jia, J., Zhu, F., Ma, X., Cao, Z., Cao, Z.W., Li, Y., Li, Y.X., and Chen, Y.Z. (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8, 111-128. Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J.S., Brown, M., Aster, J.C., and Liu, X.S. (2018). Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. Cell Syst 6, 343-354 e345. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J., Jensen, N.H., Kuijer, M.B., Matos, R.C., Tran, T.B., Whaley, R., Glennon, R.A., Hert, J., Thomas, K.L., Edwards, D.D., Shoichet, B.K., and Roth, B.L. (2009). Predicting new molecular targets for known drugs. Nature 462, 175-181. Kidd, B.A., Wroblewska, A., Boland, M.R., Agudo, J., Merad, M., Tatonetti, N.P., Brown, B.D., and Dudley, J.T. (2016). Mapping the effects of drugs on the immune system. Nat Biotechnol 34, 47-54. Knight, Z.A., Lin, H., and Shokat, K.M. (2010). Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10, 130-137. Knijnenburg, T.A., Wessels, L.F., Reinders, M.J., and Shmulevich, I. (2009). Fewer permutations, more accurate P-values. Bioinformatics 25, i161-168. Koh, C.M., Bezzi, M., Low, D.H., Ang, W.X., Teo, S.X., Gay, F.P., Al-Haddawi, M., Tan, S.Y., Osato, M., Sabo, A., Amati, B., Wee, K.B., and Guccione, E. (2015). MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96-100. Kwong, L.N., Heffernan, T.P., and Chin, L. (2013). A systems biology approach to personalizing therapeutic combinations. Cancer Discov 3, 1339-1344. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Wei, R., Carr, S.A., Lander, E.S., and Golub, T.R. (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935. Lambert, S.A., Jolma, A., Campitelli, L.F., Das, P.K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T.R., and Weirauch, M.T. (2018). The Human Transcription Factors. Cell 172, 650-665. Laplante, M., and Sabatini, D.M. (2013). Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 126, 1713-1719. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., Tang, A., Gabriel, G., Ly, C., Adamjee, S., Dame, Z.T., Han, B., Zhou, Y., and Wishart, D.S. (2014). DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42, D1091-1097. Li, J., Lenferink, A.E., Deng, Y., Collins, C., Cui, Q., Purisima, E.O., O'Connor-McCourt, M.D., and Wang, E. (2010). Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun 1, 34. Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C.T., Evans, C.P., and Gao, A.C. (2014). Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 20, 3198-3210. Liu, H., Roeder, K., and Wasserman, L. (2010). Stability Approach to Regularization Selection (StARS) for High Dimensional Graphical Models. Adv Neural Inf Process Syst 24, 1432-1440. Liu, M., Xia, Y., Ding, J., Ye, B., Zhao, E., Choi, J.H., Alptekin, A., Yan, C., Dong, Z., Huang, S., Yang, L., Cui, H., Zha, Y., and Ding, H.F. (2016). Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells. Cell Rep 17, 609-623. Liu, P., Xu, B., Li, J., and Lu, H. (2009). BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis. FEBS Lett 583, 401-406. Lizarraga, F., Espinosa, M., Ceballos-Cancino, G., Vazquez-Santillan, K., Bahena-Ocampo, I., Schwarz-Cruz, Y.C.A., Vega-Gordillo, M., Garcia Lopez, P., Maldonado, V., and Melendez-Zajgla, J. (2016). Tissue inhibitor of metalloproteinases-4 (TIMP-4) regulates stemness in cervical cancer cells. Mol Carcinog 55, 1952-1961. Locasale, J.W. (2013). Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 13, 572-583. Lopez, J.S., and Banerji, U. (2017). Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 14, 57-66. Lu, D., Liu, J.X., Endo, T., Zhou, H., Yao, S., Willert, K., Schmidt-Wolf, I.G., Kipps, T.J., and Carson, D.A. (2009). Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 4, e8294. Luo, J., Solimini, N.L., and Elledge, S.J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837. Ma, X., Liu, Y., Liu, Y., Alexandrov, L.B., Edmonson, M.N., Gawad, C., Zhou, X., Li, Y., Rusch, M.C., Easton, J., Huether, R., Gonzalez-Pena, V., Wilkinson, M.R., Hermida, L.C., Davis, S., Sioson, E., Pounds, S., Cao, X., Ries, R.E., Wang, Z., Chen, X., Dong, L., Diskin, S.J., Smith, M.A., Guidry Auvil, J.M., Meltzer, P.S., Lau, C.C., Perlman, E.J., Maris, J.M., Meshinchi, S., Hunger, S.P., Gerhard, D.S., and Zhang, J. (2018). Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371-376. Mao, Y., Fu, A., Leaderer, D., Zheng, T., Chen, K., and Zhu, Y. (2013). Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses. BMC Cancer 13, 498. Maris, J.M. (2010). Recent advances in neuroblastoma. N Engl J Med 362, 2202-2211. Martinez, R., Venturelli, D., Perrotti, D., Veronese, M.L., Kastury, K., Druck, T., Huebner, K., and Calabretta, B. (1997). Gene structure, promoter activity, and chromosomal location of the DR-nm23 gene, a related member of the nm23 gene family. Cancer Res 57, 1180-1187. Massey, F.J. (1951). The Kolmogorov-Smirnov Test for Goodness of Fit. J Am Stat Assoc 46, 68-78. Matthay, K.K., Maris, J.M., Schleiermacher, G., Nakagawara, A., Mackall, C.L., Diller, L., and Weiss, W.A. (2016). Neuroblastoma. Nat Rev Dis Primers 2, 16078. Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., Swift, P., Shimada, H., Black, C.T., Brodeur, G.M., Gerbing, R.B., and Reynolds, C.P. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341, 1165-1173. Menche, J., Sharma, A., Kitsak, M., Ghiassian, S.D., Vidal, M., Loscalzo, J., and Barabasi, A.L. (2015). Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601. Moffat, J.G., Rudolph, J., and Bailey, D. (2014). Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov 13, 588-602. Molitoris, J.K., McColl, K.S., Swerdlow, S., Matsuyama, M., Lam, M., Finkel, T.H., Matsuyama, S., and Distelhorst, C.W. (2011). Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. J Biol Chem 286, 30181-30189. Mosse, Y.P., Laudenslager, M., Longo, L., Cole, K.A., Wood, A., Attiyeh, E.F., Laquaglia, M.J., Sennett, R., Lynch, J.E., Perri, P., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N.J., Brodeur, G.M., Tonini, G.P., Rappaport, E., Devoto, M., and Maris, J.M. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935. Muller, F.J., Laurent, L.C., Kostka, D., Ulitsky, I., Williams, R., Lu, C., Park, I.H., Rao, M.S., Shamir, R., Schwartz, P.H., Schmidt, N.O., and Loring, J.F. (2008). Regulatory networks define phenotypic classes of human stem cell lines. Nature 455, 401-405. Nagel, R., Semenova, E.A., and Berns, A. (2016). Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep 17, 1516-1531. Niepel, M., Hafner, M., Duan, Q., Wang, Z., Paull, E.O., Chung, M., Lu, X., Stuart, J.M., Golub, T.R., Subramanian, A., Ma'ayan, A., and Sorger, P.K. (2017). Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun 8, 1186. Nilsson, R., Jain, M., Madhusudhan, N., Sheppard, N.G., Strittmatter, L., Kampf, C., Huang, J., Asplund, A., and Mootha, V.K. (2014). Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 5, 3128. Nitiss, J.L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9, 338-350. Oberthuer, A., Juraeva, D., Li, L., Kahlert, Y., Westermann, F., Eils, R., Berthold, F., Shi, L., Wolfinger, R.D., Fischer, M., and Brors, B. (2010). Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 10, 258-266. Osada, T., Chen, M., Yang, X.Y., Spasojevic, I., Vandeusen, J.B., Hsu, D., Clary, B.M., Clay, T.M., Chen, W., Morse, M.A., and Lyerly, H.K. (2011). Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 71, 4172-4182. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S., and Hopkins, A.L. (2006). Global mapping of pharmacological space. Nat Biotechnol 24, 805-815. Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Kramer, A., Roncaioli, J.L., Sand, F., Heuckmann, J.M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmuller, J., Nurnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K.O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M.R., Savelyeva, L., Watkins, S.C., Shao, C., Bell, E., Hofer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Buttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J.H., Herrmann, C., O'Sullivan, R.J., Westermann, F., Thomas, R.K., and Fischer, M. (2015). Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700-704. Perez-Iglesias, R., Mata, I., Pelayo-Teran, J.M., Amado, J.A., Garcia-Unzueta, M.T., Berja, A., Martinez-Garcia, O., Vazquez-Barquero, J.L., and Crespo-Facorro, B. (2009). Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res 107, 115-121. Perne, A., Muellner, M.K., Steinrueck, M., Craig-Mueller, N., Mayerhofer, J., Schwarzinger, I., Sloane, M., Uras, I.Z., Hoermann, G., Nijman, S.M., and Mayerhofer, M. (2009). Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 4, e8292. Pugh, T.J., Morozova, O., Attiyeh, E.F., Asgharzadeh, S., Wei, J.S., Auclair, D., Carter, S.L., Cibulskis, K., Hanna, M., Kiezun, A., Kim, J., Lawrence, M.S., Lichenstein, L., McKenna, A., Pedamallu, C.S., Ramos, A.H., Shefler, E., Sivachenko, A., Sougnez, C., Stewart, C., Ally, A., Birol, I., Chiu, R., Corbett, R.D., Hirst, M., Jackman, S.D., Kamoh, B., Khodabakshi, A.H., Krzywinski, M., Lo, A., Moore, R.A., Mungall, K.L., Qian, J., Tam, A., Thiessen, N., Zhao, Y., Cole, K.A., Diamond, M., Diskin, S.J., Mosse, Y.P., Wood, A.C., Ji, L., Sposto, R., Badgett, T., London, W.B., Moyer, Y., Gastier-Foster, J.M., Smith, M.A., Guidry Auvil, J.M., Gerhard, D.S., Hogarty, M.D., Jones, S.J., Lander, E.S., Gabriel, S.B., Getz, G., Seeger, R.C., Khan, J., Marra, M.A., Meyerson, M., and Maris, J.M. (2013). The genetic landscape of high-risk neuroblastoma. Nat Genet 45, 279-284. Puissant, A., Frumm, S.M., Alexe, G., Bassil, C.F., Qi, J., Chanthery, Y.H., Nekritz, E.A., Zeid, R., Gustafson, W.C., Greninger, P., Garnett, M.J., McDermott, U., Benes, C.H., Kung, A.L., Weiss, W.A., Bradner, J.E., and Stegmaier, K. (2013). Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3, 308-323. Rader, J., Russell, M.R., Hart, L.S., Nakazawa, M.S., Belcastro, L.T., Martinez, D., Li, Y., Carpenter, E.L., Attiyeh, E.F., Diskin, S.J., Kim, S., Parasuraman, S., Caponigro, G., Schnepp, R.W., Wood, A.C., Pawel, B., Cole, K.A., and Maris, J.M. (2013). Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19, 6173-6182. Radhakrishnan, S.K., Lee, C.S., Young, P., Beskow, A., Chan, J.Y., and Deshaies, R.J. (2010). Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell 38, 17-28. Ramirez, M., Rajaram, S., Steininger, R.J., Osipchuk, D., Roth, M.A., Morinishi, L.S., Evans, L., Ji, W., Hsu, C.H., Thurley, K., Wei, S., Zhou, A., Koduru, P.R., Posner, B.A., Wu, L.F., and Altschuler, S.J. (2016). Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 7, 10690. Reddy, A.S., and Zhang, S. (2013). Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol 6, 41-47. Rees, M.G., Seashore-Ludlow, B., Cheah, J.H., Adams, D.J., Price, E.V., Gill, S., Javaid, S., Coletti, M.E., Jones, V.L., Bodycombe, N.E., Soule, C.K., Alexander, B., Li, A., Montgomery, P., Kotz, J.D., Hon, C.S., Munoz, B., Liefeld, T., Dancik, V., Haber, D.A., Clish, C.B., Bittker, J.A., Palmer, M., Wagner, B.K., Clemons, P.A., Shamji, A.F., and Schreiber, S.L. (2016). Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 12, 109-116. Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., and Ding, K. (2010). Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett 1, 454-459. Rosati, A., Graziano, V., De Laurenzi, V., Pascale, M., and Turco, M.C. (2011). BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis 2, e141. Ryall, K.A., and Tan, A.C. (2015). Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform 7, 7. Santos, R., Ursu, O., Gaulton, A., Bento, A.P., Donadi, R.S., Bologa, C.G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T.I., and Overington, J.P. (2017). A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16, 19-34. Saunders, N.A., Simpson, F., Thompson, E.W., Hill, M.M., Endo-Munoz, L., Leggatt, G., Minchin, R.F., and Guminski, A. (2012). Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 4, 675-684. Schramm, A., Koster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schroder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmulle | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73357 | - |
dc.description.abstract | 我的論文包含利用基因表現於癌症藥物探索之三個章節。完成這項研究工作主要是藉由分析美國國家衛生研究院所資助LINCS計劃藥物擾動基因表現圖譜公開巨量資料。第一章介紹一個從基因表現衡量藥物相似度的新度量,在藥物分群上優於其他最先進的度量。第二章呈現一種尋找組合藥物的方法,利用藥物誘發基因標記針對癌症依賴性進行攻擊。第三章描述一項在高危險群神經母細胞瘤進行整合基因分析之研究,並找到有效治療藥物。
相較於傳統藥物開發環繞在「單一藥物結合單一標靶」之概念,近年來藥物實際上普遍具有之「多標靶藥理」特性(即單一藥物能結合多重標靶)逐漸受到醫學界重視,甚至對於某些疾病之有效治療是必需的。我們利用LINCS巨量藥物擾動基因圖譜資料,剖析複雜多標靶藥理現象,藉以探索舊藥新用與組合治療之可能性,縮短藥物研發總時程。 在第一章,我們首先利用藥物擾動基因表現變化強度大小之特點,開發一個衡量藥物之間相似度的新度量,並證明這個新度量比其他常用度量能更準確地將已知相同作用機制之藥物分類在一起,成功運用它找到可能具有拓樸酶抑制劑活性的非抗癌用上市藥。 癌細胞生長除了仰賴自身致癌突變基因,也會高度依靠一些非突變基因之功能,這兩種現象分別稱為「癌基因成癮」與「非癌基因成癮」。在第二章,我們藉由分析LINCS巨量資料,系統性揭示藥物誘發基因標記,發現其與癌症特徵以及藥物敏感性息息相關,並進一步完成相關藥效評估試驗。本章節從非癌基因成癮之角度,提供新穎藥物與組合治療策略,在精準醫學上具有潛在應用價值。 神經母細胞瘤是一種罕見兒童惡性腫瘤,其基因突變之高度異質性,使得標靶治療應用仍相當有限。此外高危險群患者其五年存活率僅不到40%。為尋找有效治療藥物,在第三章中我們利用GEO公開資料庫,針對近千名神經母細胞瘤患者腫瘤基因圖譜資料進行整合分析,發現與高危險群相關之非癌成癮基因,並結合LINCS藥物誘發基因標記成功預測了一些具有潛力之新藥,並在老鼠體內驗證抗寄生蟲藥耐克螺之抗神經母細胞瘤活性,並利用蛋白質體學闡述其作用機制。 總結而言,這些章節呈現另一種從基因表現之觀點,為複雜性疾病尋找新穎治療藥物,特別適用於那些具有極少分子標靶或對標準治療產生抗藥性之腫瘤。這一系列基因表現分析方法與成果為藥物研究與癌症治療取得重大進展。 | zh_TW |
dc.description.abstract | My thesis contains three chapters that were dedicated to cancer drug discovery using gene expression. This was made possible by analyzing a large compendium of publicly accessible perturbational gene-expression profiles obtained from the Library of Integrated Network-based Cellular Signatures (LINCS), a project initiated by the US National Institute of Health. The first chapter introduces a new gene expression similarity metric that surpasses other state-of-the-art metrics in drug clustering and repurposing. The second chapter presents an approach that uses small-molecule signatures to target tumor dependencies for combinatorial drug discovery. The third chapter describes an integrated transcriptome analysis in high-risk neuroblastoma, leading to identification of effective drug treatments.
Compared with the traditional drug-development paradigm whereby “a single drug should bind to a single target”, the phenomenon of drug promiscuity, or polypharmacology, whereby a single drug can bind to multiple targets, has been recently attracting much attention in the medical community. This polypharmacology is probably even indispensable for effective treatment in some medications. We investigated the complex polypharmacological interactions mirrored in the compound-perturbed gene expression profiles to explore new opportunities for combinatorial drug therapy and repurposing, which will help to substantially reduce the cost and time spent on drug research and development. In the first chapter, we developed a gene expression similarity metric that directly emphasizes the genes exhibiting the greatest changes in expression in response to a perturbation. This metric was proved to outperform other state-of-the-art and commonly used metrics in a clustering task of given known drugs with diverse mechanisms of action. We then applied this metric to systematically compare thousands of small-molecule perturbations across 10 cell types and further investigated an anthelmintic and a loop diuretic as potential topoisomerase inhibitors for anticancer therapy. Along with the dependency on driver mutations that confer growth advantage, cancer cells can also develop an addiction to certain genes that are themselves not oncogenic but whose functions are required for maintenance of the tumorigenic state. These needs of both oncogenes and non-mutated genes for cancer cell survival are coined as oncogene and non-oncogene addictions, respectively. In the second chapter, we systematically analyzed a large compendium of compound-perturbed data to uncover several perturbational gene-expression signatures that are highly correlated with cancer hallmark and drug sensitivity. We then developed a computational approach that uses these small-molecule signatures to target non-oncogene tumor dependencies for combinatorial drug discovery and experimentally confirmed two unexpected drug pairs with synergistic killing. This chapter provides an alternative drug discovery strategy from non-oncogene addiction and has potential clinical applicability to guide future combination therapy in precision medicine. Neuroblastoma is a rare pediatric malignancy, whose heterogeneous mutational spectrum has restricted the development of targeted therapies. Despite intensive treatment, survival for high-risk neuroblastoma still remains below 40%. To address this unmet need, we performed, in the third chapter, an integrative transcriptomic analysis of nearly a thou-sand patients with primary neuroblastoma obtained from multiple Gene Expression Omnibus (GEO) datasets to identify potential drugs that target non-oncogene dependencies in high-risk neuroblastoma. Among these predictions, we demonstrated the in vivo efficacy of niclosamide, an anthelmintic drug approved by the US FDA to treat tapeworm infections, and further investigated its mechanism of action through proteomics. Collectively, these chapters present an alternative insight from gene-expression perspective to identify novel therapeutic options for complex diseases, particularly useful for tumors with few druggable molecular targets or acquired resistance to standard therapies. The methods and results from this collection represent important and significant advances in drug research and cancer therapy, achieved with gene expression analysis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:30:19Z (GMT). No. of bitstreams: 1 ntu-108-D01945012-1.pdf: 124396201 bytes, checksum: b3907a20bc8ad1c79adbe07d0c051caa (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Abstract 1
摘要 4 Chapter I: A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning 6 Summary 7 Introduction 8 Materials and Methods 12 Results 30 Discussion 43 Figures 47 Tables 74 Chapter II: Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery 76 Summary 77 Introduction 78 Materials and Methods 83 Results 101 Discussion 115 Figures 122 Tables 142 Chapter III: Therapeutic Targeting of Non-Oncogene Dependencies in High-Risk Neuroblastoma 144 Summary 145 Introduction 146 Materials and Methods 149 Results 171 Discussion 180 Figures 188 Tables 207 Future Perspectives 209 References 211 | |
dc.language.iso | en | |
dc.title | 開發基因表現分析方法於藥物探索與癌症治療 | zh_TW |
dc.title | Developing Gene-Expression-Based Approaches for Drug
Discovery and Cancer Therapy | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 歐陽彥正 | |
dc.contributor.oralexamcommittee | 黃宣誠,陳倩瑜,蔡懷寬,曾新穆,林文昌 | |
dc.subject.keyword | 癌症藥物探索,組合治療,基因表現分析,非癌基因成癮,神經母細胞瘤, | zh_TW |
dc.subject.keyword | cancer drug discovery,combination therapy,gene expression analysis,non-oncogene addiction,neuroblastoma, | en |
dc.relation.page | 240 | |
dc.identifier.doi | 10.6342/NTU201900904 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-06-14 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 121.48 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。